Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.

NCT00657904 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00657904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00657904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
August 31, 1995
Completion date
August 31, 2008
Enrollment
3,618 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic prostate cancer